BridgeBio Pharma Inc [NASDAQ: BBIO] surged by $0.5 during the normal trading session on while it closed the day at $38.02.
BridgeBio Pharma Inc stock has also gained 17.85% of its value over the past 7 days. However, BBIO stock has inclined by 8.72% in the 3 months of the year. Over the past six months meanwhile, it has gained 40.35% and gained 38.56% year-on date.
The market cap for BBIO stock reached $7.22 billion, with 189.83 million shares outstanding and 160.74 million shares in the current float. Compared to the average trading volume of 2.96M shares, BBIO reached a trading volume of 3502996 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BridgeBio Pharma Inc [BBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $60.53 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.37. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Redburn Atlantic have made an estimate for BridgeBio Pharma Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 31, 2025. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on October 16, 2024, representing the official price target for BridgeBio Pharma Inc stock.
The Average True Range (ATR) for BridgeBio Pharma Inc is set at 1.58, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 56.66.
BBIO stock trade performance evaluation
BridgeBio Pharma Inc [BBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.85. With this latest performance, BBIO shares dropped by -0.52% in over the last four-week period, additionally plugging by 40.35% over the last 6 months – not to mention a rise of 35.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 65.81, with the RSI for the last a single of trading hit 73.99, and the three-weeks RSI is set at 61.13 for BridgeBio Pharma Inc [BBIO]. The present Moving Average for the last 50 days of trading for this stock 34.65, while it was recorded at 35.72 for the last single week of trading, and 30.27 for the last 200 days.
BridgeBio Pharma Inc [BBIO]: An insightful look at the core fundamentals
BridgeBio Pharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.54 and a Current Ratio set at 4.57.
BridgeBio Pharma Inc [BBIO]: Institutional Ownership
The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 31.06 million shares, which is approximately 16.5582%. VIKING GLOBAL INVESTORS LP, holding 25.12 million shares of the stock with an approximate value of $$636.31 million in BBIO stocks shares; and VIKING GLOBAL INVESTORS LP, currently with $$356.01 million in BBIO stock with ownership which is approximately 7.4924%.
